Changes in T-cell numbers and plasma immunoglobulin levels during therapy with lenalidomide. (A) Peripheral CD3+ T-cell numbers (mean values ± 1 standard deviation) measured at baseline and during treatment with lenalidomide in 31 LTRs. (B) Percentages of CD4 and CD8+ measured at baseline and during treatment with lenalidomide in 31 LTRs. Baseline median absolute value of CD4 and CD8 was 271 and 176 × 103/mL, respectively, and after 60 months increased to 456 and 362 × 103/mL, respectively. (C) Increase in plasma immunoglobulin measured in 31 LTRs during treatment with lenalidomide when compared with baseline (P < .001) . Values are expressed as percentage change from baseline, mean values ± 1 standard deviation. Median baseline were IgG, 729 (180-3560) mg/dL; IgA, 91 (15-223) mg/dL; and IgM, 27 (0-485) mg/dL. Baseline IgG, IgA, and IgM levels were less than the normal range in 15 (43%), 14 (40%), and 22 (63%) LTRs, and later normalized in 58%, 57%, and 45% of them, respectively.
